ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

Mass. Requires Coverage of Routine Patient Care In Clinical Trials

September 6, 2002

In Brief: Glantz, Waxman, Wigand honored For Work Opposing tobacco; CTRC Names Executives

February 16, 1996

Addition of Immune Stimulant To Yervoy Therapy Increases Overall Survival, Study Says

November 28, 2014

CDC To Award $23 Mil. To States for Screening

April 26, 1991

Sales of Smoking Cessation Aids Increase, Effectiveness Drops

October 25, 2002

FDA Approves Ribavirin Phase 102 Trials

October 30, 1987